openPR Logo
Press release

Hepatitis C Drugs Market - What are the Short and long-term actions taken by Key Players During Coronavirus Pandemic? Prominent Players : Abbvie Inc. , Gilead Sciences Inc. , Bristol-Myers Squibb Company , Janssen Pharmaceuticals Inc. , Merck Sharp & Dohm

06-03-2020 05:48 PM CET | Health & Medicine

Press release from: Fortune Business Insights

Hepatitis C Drugs Market

Hepatitis C Drugs Market

The global hepatitis C drugs market will derive growth impetus from the high prevalence of hepatitis C across the world. According to a report published by Fortune Business Insights, titled “Hepatitis C Drugs: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 7,866.6 Mn in 2018. Fortune Business Insights states that the market is projected to reach US$ 7,351.7 Mn by 2026, exhibiting a CAGR of -0.9% in the forecast period.

Hepatitis C is a viral infection that causes severe damage such as inflammation of the liver and can spread through contaminated blood. The advanced stages of hepatitis C can also lead to liver damage, thereby creating severe health risks. The severity of hepatitis C has created a huge emphasis on the research and development of drugs associated with the treatment of this disease. Several new drugs have been launched in recent times, due to the high prevalence of hepatitis C across the world. Hepatitis C requires oral injections and dosages on a weekly basis, and it also has several side effects that can also lead to permanent damage. Increasing clinical trials and successful drug clearances have aided the overall growth of the global hepatitis C market. Increasing number of regulatory approvals will boost the global hepatitis C market in the forthcoming years.

Request a Sample Copy of the Research Report:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hepatitis-c-drug-market-101562

The report covers :
o Global Hepatitis C Drugs Market trends, with detailed analysis on consumer trends & manufacturer trends.
o Overview on supply analysis covering trends across raw material suppliers, technology providers and distributors.
o Key areas of investments identifying market opportunities and challenges in forecast time frame.
o Competitive analysis of the industry players along with the overview on strategic management.
o Comprehensive company profiles of the major industry players.

An Overview of the Impact of COVID-19 on this Market :
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for the future.

Click here to get the short-term and long-term impact of COVID-19 on this [Market].

Please visit : https://www.fortunebusinessinsights.com/industry-reports/hepatitis-c-drug-market-101562

Increasing Drug Approvals Will Favor Market Growth
The escalating demand for hepatitis C drugs has yielded several regulatory approvals for associated drugs. Fortune Business Insights has predicted that increasing regulatory approvals for related drugs and recombinant products will constitute an increase in the global hepatitis C drugs market value in the coming years. The hepatitis C drugs industry has witnessed numerous drug approvals in recent years driven by the increasing fatality rate of the disease. In April 2019, the United States Food and Drug Administration passed approval for Mavyret for the treatment of hepatitis C in pediatric patients. The Mavyret was the first treatment for all genotypes of hepatitis C. The 2017 approval for the same drug was aimed at the treatment of hepatitis C, but in patients without cirrhosis or mild cirrhosis of the liver. Fortune Business Insights has predicted that AbbVie’s successful drug approval will help the company generate a substantial amount of hepatitis C market value. The report includes some major regulatory approvals of recent times and gauges the impact of these drug approvals on the global hepatitis C drugs market.

Leading Players operating in the Hepatitis C Drugs Market are :

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
• Abbvie Inc.
• Gilead Sciences Inc.
• Bristol-Myers Squibb Company
• Janssen Pharmaceuticals Inc.
• Merck Sharp & Dohme Corp.
• F.Hoffmann-La Roche Ltd
• Vertex Pharmaceuticals Incorporated
• Other Prominent Players

Huge Hepatitis C Patient Pool Will Offer Growth Opportunities for the Market in North America
The high prevalence of hepatitis C has created a need for efficient drugs at low cost. Fortune Business Insights has identified increasing hepatitis C incidence as a primary growth driver. The increased adoption of hepatitis C drugs will favor the growth of the market in North America. Fortune Business Insights has predicted that the hepatitis C drugs market in North America will witness considerable growth, driven by the high demand for hepatitis C drugs. Furthermore, recent drug advancements will fuel the demand for related drugs, subsequently aiding market growth. Fortune Business Insights states that the hepatitis C drugs market in North America was valued at US$ 3,736.6 Mn in 2018.

Fortune Business Insights profiles a few of the prominent companies that are operating in the global market. Some of the leading companies that have established standout market positions are AbbVie Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., F. Hoffmann-La Roche Ltd, and Vertex Pharmaceuticals Incorporated.

Have Any Query? Ask Our Experts :
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/hepatitis-c-drug-market-101562

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges

Contact Us:
Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatitis C Drugs Market - What are the Short and long-term actions taken by Key Players During Coronavirus Pandemic? Prominent Players : Abbvie Inc. , Gilead Sciences Inc. , Bristol-Myers Squibb Company , Janssen Pharmaceuticals Inc. , Merck Sharp & Dohm here

News-ID: 2066418 • Views: 282

More Releases from Fortune Business Insights

Automotive Airless Tire Industry Forecast 2030 - Featuring MICHELIN, Bridgestone …
Final Report will add the Impact of COVID-19 Analysis on Automotive Airless Tire Industry: The global automotive airless tire market is anticipated to gain momentum from the increasing sales and production of light and passenger commercial vehicles. Additionally, the governments of several countries have put forward strict laws for vehicle manufacturers to use environment-friendly components to control the emission of carbon. Hence, the manufacturers are using airless tires as they possess
North America Connected Car Industry Forecast 2030 - Featuring Kawasaki and more
Final Report will add the Impact of COVID-19 Analysis on North America Connected Car Industry: The global North America Connected Car market is likely to rise at a considerable pace driven by the presence of several large scale companies operating across the world. The North America Connected Car size is anticipated to reach high USD value by 2027. Further, the market is anticipated to exhibit a highest CAGR Rate during the
Connected Car Industry Forecast 2030 - Featuring Bayerische Motoren Werke AG (BM …
Final Report will add the Impact of COVID-19 Analysis on Connected Car Industry: The global connected car market size is predicted to reach USD 142.49 billion by 2026, exhibiting a CAGR of 16.4% during the forecast period. The growing R&D for the advancement in connecting systems will enable speedy growth of the market during the forecast period. In addition, the rising passenger cars around the world is predicted to contribute positively
Fuel Cell Vehicle Industry Forecast 2030 - Featuring BMW AG, Daimler AG, Hyundai …
Final Report will add the Impact of COVID-19 Analysis on Fuel Cell Vehicle Industry: The global fuel cell vehicle market size is set to touch USD 6,731.4 million by 2026, exhibiting a staggering 29.7% CAGR during the forecast period. Increasing air pollution levels caused by cars and other vehicles will propel the growth of this market, according to the new Fortune Business Insights™ report, titled “Fuel Cell Vehicle Market Size, Share

All 5 Releases


More Releases for Hepatitis

Hepatitis E Therapeutics Pipeline Analysis 2018
Hepatitis E is a liver disease caused by infection due to a virus known as hepatitis E virus (HEV). This disease can cause swelling in liver. Some of the common symptoms are mild fever, feeling of tiredness, feeling sick to stomach, and belly pain. Download the sample report at: https://www.pharmaproff.com/request-sample/1029 The World Health Organization (WHO) estimates released in 2018 stated that, every year, an estimated 20 million HEV infections worldwide, leading to
Hepatitis Drugs Market Opportunity Assessment Study
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market The increasing incidences of various types of hepatitis, such as hepatitis B, and hepatitis C are playing a pivotal role in
Global Hepatitis A Vaccine Sales Market Report
In this report, the global Hepatitis A Vaccine market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Hepatitis A Vaccine for these regions, from 2013
Hepatitis B Vaccines Market Growth Analysis 2021
Hepatitis B refers to an infectious disease that is caused by hepatitis B virus. Symptoms of this disease are not visible in initial stages and develop after few weeks only. Hepatitis B virus is transmitted by exposure to infectious blood or body fluids of an infected person. This disease may even occur from the birth. Hepatitis B may be caused by blood transfusions, healthcare setting, sharing razors and dialysis. Hepatitis
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Global Hepatitis C Drug Sales Market 2017
In this report, the Global Hepatitis C Drug Market 2017 is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Hepatitis C Drug for these regions, from 2012